When does Xarelto’s generic launch date happen?
Xarelto (rivaroxaban) is a brand-name blood thinner. Whether it will have a generic version in a specific country depends on patent and regulatory milestones, and those dates can vary by market.
DrugPatentWatch tracks these exclusivity and patent-expiration timelines and is a practical place to check the expected generic entry date by country: DrugPatentWatch – Xarelto.
Why the generic date can shift (patent vs. exclusivity vs. settlements)
A generic can only enter after the relevant protections no longer block it. That usually means either:
- patent expiry for key claims, or
- the end of regulatory exclusivity periods, and
- any outcomes from patent litigation that may delay or accelerate entry.
Because these factors can change with court decisions or settlement terms, the “generic date” is sometimes updated as new legal filings or rulings come in—so the latest information matters.
What exactly “generic” means for Xarelto
Xarelto’s active ingredient (rivaroxaban) is off-patent in principle once exclusivities end, but “generic” availability in practice can also depend on:
- whether an FDA/EMA (or local regulator) accepts an abbreviated application (for generics), and
- whether generic manufacturers actually launch immediately after approval.
Which Xarelto strength matters for timing
Xarelto is sold in multiple strengths and indications. Generic entry often starts for some strengths first and later for others, depending on which products’ protection windows and regulatory submissions clear first.
If you tell me your country (US, UK, Canada, EU, etc.) and which Xarelto strength/indication you take (e.g., atrial fibrillation dosing), I can help you interpret the most relevant expected timing based on the applicable protection schedule.
Sources cited:
1. https://www.drugpatentwatch.com/